ChromaDex Capitalizes On Longevity Boom But Valuation Remains High
ChromaDex Corporation shows strong revenue growth and profitability, driven by its NAD+ precursors and flagship product Niagen, despite high valuation and execution risks. Record-breaking financial performance includes a 37.41% revenue increase, $7.2 million net income, and expanded gross margins, with a significant e-commerce boost. The company faces challenges like supply chain issues, tariff risks, and regulatory uncertainties, which could impact its ambitious growth targets and market position.
ChromaDex Corporation (CDXC) Q4 2024 Earnings Call Transcript
ChromaDex Corporation (NASDAQ:CDXC ) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET Company Participants Ben Shamsian - Vice President, Lytham Partners, Investor Relations Rob Fried - Chief Executive Officer Ozan Pamir - Chief Financial Officer Andrew Shao - SVP, Scientific & Regulatory Affairs Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Mitchell Pinheiro - Sturdivant Bill Dezellem - Tieton Capital Management Ram Selvaraju - H.C. Wainwright Sean McGowan - ROTH Capital J.P.
ChromaDex (CDXC) Q4 Earnings and Revenues Surpass Estimates
ChromaDex (CDXC) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to break-even earnings per share a year ago.
ChromaDex (CDXC) is on the Move, Here's Why the Trend Could be Sustainable
If you are looking for stocks that are well positioned to maintain their recent uptrend, ChromaDex (CDXC) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
ChromaDex Corporation (CDXC) Hits Fresh High: Is There Still Room to Run?
ChromaDex (CDXC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Recent Price Trend in ChromaDex (CDXC) is Your Friend, Here's Why
ChromaDex (CDXC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
What Makes ChromaDex (CDXC) a Strong Momentum Stock: Buy Now?
Does ChromaDex (CDXC) have what it takes to be a top stock pick for momentum investors? Let's find out.
ChromaDex Corporation (CDXC) Hit a 52 Week High, Can the Run Continue?
ChromaDex (CDXC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
ChromaDex (CDXC) Is a Great Choice for 'Trend' Investors, Here's Why
ChromaDex (CDXC) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
ChromaDex Corporation (CDXC) Q3 2024 Earnings Call Transcript
ChromaDex Corporation (NASDAQ:CDXC ) Q3 2024 Earnings Conference Call October 31, 2024 4:30 PM ET Company Participants Ben Shamsian - IR Rob Fried - CEO Ozan Pamir - CFO Andrew Shao - SVP, Scientific & Regulatory Affairs Wesley Yu - VP, Finance Conference Call Participants Jeff Cohen - Ladenburg Thalmann & Co. Edward Marks - H.C. Wainwright Bill Dezellem - Tieton Capital Management Sean McGowan - ROTH MKM Partners J.P.
ChromaDex (CDXC) Beats Q3 Earnings and Revenue Estimates
ChromaDex (CDXC) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to loss of $0.01 per share a year ago.
ChromaDex Gears Up to Report Q3 Earnings: Here's What to Expect
On CDXC's third-quarter 2024 earnings call, investors' focus is likely to be on the sales numbers of its marketed product Niagen and updates on the pipeline.
